Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease
about
Modulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE⁻/⁻ miceGetting to the heart of intracellular glucocorticoid regeneration: 11β-HSD1 in the myocardiumEndothelial Response to Glucocorticoids in Inflammatory DiseasesGlucocorticoid signaling in the heart: A cardiomyocyte perspectiveVirtual screening as a strategy for the identification of xenobiotics disrupting corticosteroid actionDual role for glucocorticoids in cardiomyocyte hypertrophy and apoptosisThe Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors.Application of an integrative computational framework in trancriptomic data of atherosclerotic mice suggests numerous molecular players.Glucocorticoid-mediated inhibition of angiogenic changes in human endothelial cells is not caused by reductions in cell proliferation or migrationA novel 11β-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6/J mice with a potential to provide cardio protective benefits.A neuroendocrine mechanism of co-morbidity of depression-like behavior and myocardial injury in rats.Endothelial glucocorticoid receptor suppresses atherogenesis--brief reportDisplacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist.Vascular Dysfunction in Horses with Endocrinopathic Laminitis.Impaired oxidoreduction by 11β-hydroxysteroid dehydrogenase 1 results in the accumulation of 7-oxolithocholic acid.Glucocorticoid resistance of migration and gene expression in a daughter MDA-MB-231 breast tumour cell line selected for high metastatic potential.Contribution of endogenous glucocorticoids and their intravascular metabolism by 11β-HSDs to postangioplasty neointimal proliferation in mice.Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11betaHSD1-deficient mice post-MI.Glucocorticoids and renal Na+ transport: implications for hypertension and salt sensitivity.Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity.Coronary stents: historical development, current status and future directions.11β-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease.Maternal undernutrition and fetal developmental programming of obesity: the glucocorticoid connection.Atherosclerosis associated with vasculopathic lesions in a golden retriever with hypercholesterolemia.Inhibition of proteasome-mediated glucocorticoid receptor degradation restores nitric oxide bioavailability in myocardial endothelial cells in vitro.Reciprocal regulation of 11β-hydroxysteroid dehydrogenase 1 and glucocorticoid receptor expression by dexamethasone inhibits human coronary artery smooth muscle cell proliferation in vitro.Coronary slow flow accompanying exertional blurred vision and effects of corticosteroids.Endothelial glucocorticoid receptor promoter methylation according to dexamethasone sensitivity.Changes in 11β-Hydroxysteroid Dehydrogenase and Glucocorticoid Receptor Expression in Kawasaki Disease.Role of BCL2-associated athanogene 1 in differential sensitivity of human endothelial cells to glucocorticoids.Hepatic reduction of the secondary bile acid 7-oxolithocholic acid is mediated by 11β-hydroxysteroid dehydrogenase 1.Hypothalamic-Pituitary-Adrenal Axis Modulation of Glucocorticoids in the Cardiovascular System.Auto-amplification of cortisol actions in human carotid atheroma is linked to arterial remodeling and stroke.Genomic and rapid effects of aldosterone: what we know and do not know thus far.Obesity and cortisol: New perspectives on an old theme.Definitions and pathophysiology of vasoplegic shock.Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trialA pilot study of the effects of eplerenone add-on therapy in patients taking renin–angiotensin system blockers
P2860
Q26998660-1C23760B-822C-48D0-9AC0-66BE4D909F06Q27322801-6A48721B-637F-465B-8A07-485E8226F95EQ28067162-5558F9B4-A6D8-472C-B9B1-E29A5EC8A52FQ28073947-3C7347B4-6A8C-4FA9-A104-FF956C3DE590Q28083936-0F940146-3564-45A8-BBD0-A34F61CF6B5AQ28484229-21E2E0C5-E2BF-4854-A727-76F274BE0146Q28580617-A9A352F4-CB85-42EC-B166-79EEE44A2A2FQ30486738-A267B05A-4240-4EAF-B557-594B5C381C62Q30578906-DD252095-C984-4329-A4C8-A8CF4D5FF142Q33789118-50202CB2-3AB0-4867-B4C9-A01BE57BD01EQ34023395-59A6A18B-C12F-4CB3-BEE1-17F777480486Q35097384-D207A556-3CCF-4B14-BE69-21B6546A97C9Q35222164-734377CE-77F0-4BCC-ACCB-7062857CF739Q35358929-7DE1BB52-FB0F-4D6E-AFAC-47D4CD9B90CEQ36147976-8A3B56E6-6E0B-4907-AAD1-C2EF7A3ABA6DQ37163081-9FC0F5BC-85B4-4B13-BF66-89B299397110Q37682224-F0C8122D-8DF9-4FD8-948A-45B3F9E075FDQ37687150-21A8FB69-C67C-4B30-8AD6-79FB7551BEE8Q37722843-4D5D17A2-1DFE-437B-B6D2-E89C9B811002Q37727017-1FBD4002-18FD-4423-ACB6-28203528A0F8Q37859676-E3CAD5BA-A6DC-4CEC-BD3C-1EA7D402C1CCQ38093501-6CBEE015-53CC-42CA-9969-27D3B318E64CQ38132710-5E617797-4FCD-42A2-909E-D1AF89F7E550Q38226986-4658FDBA-9117-47F0-A24D-8E638C426EA5Q38836297-6CB55E6A-7F56-49EC-B0A9-05F23CC9F0ACQ39002555-23BAAC96-1258-4B18-ABD4-85A18631001CQ41259479-E88CCB51-B06E-4415-B345-2C4F0D5F75A9Q41483303-057A5C0E-DB72-4F87-81E9-B6FCDEAE41DAQ42061655-522891F7-D657-4B90-9406-5EF80C33162FQ42237316-DD7C7E4F-3814-4B51-A7A5-FCCA373B2676Q42356932-D27457D5-13A2-439F-8A2E-3024A019AC8EQ42744337-003C6085-FF85-49F5-A97A-749E5D4FD4FEQ45351708-674BD93C-8A86-4DC3-AB93-E169E04DD641Q46664468-E93B9B81-C2E2-49C1-8F96-6E9A80CCD621Q51273122-91FE3B20-8D61-4322-A8B6-B2198CE76BB9Q53484842-94353903-ABBD-4AC1-8E43-C7C2B4EC96BAQ55510405-105776D2-73B0-4A3A-A12D-E8AD6C3CA399Q57985961-F82442B4-7EB2-4F79-95E3-940838DDE288Q58362621-F2CC5227-BC17-4D02-88FA-B3715A1580A9
P2860
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease
@en
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.
@nl
type
label
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease
@en
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.
@nl
prefLabel
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease
@en
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.
@nl
P2860
P1476
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease
@en
P2093
Brian R Walker
Patrick W F Hadoke
P2860
P304
P356
10.1111/J.1476-5381.2008.00047.X
P407
P50
P577
2009-02-23T00:00:00Z